Screening to prevent polyoma virus nephropathy in kidney transplantation: a cost analysis

Am J Transplant. 2009 Sep;9(9):2177-9. doi: 10.1111/j.1600-6143.2009.02729.x. Epub 2009 Jun 26.

Abstract

Polyoma virus nephropathy is an important cause of graft dysfunction in kidney transplant recipients and screening to prevent disease has been advocated. Although screening incurs new costs, our hypothesis is that savings from less immunosuppression in those with positive screening tests could pay for overall costs of screening. In 134 consecutive recipients, polyoma virus (positive decoy cells) was detected in the urine of 34 (25.4%) individuals over a 2-year follow-up. Of these 34, 11 had a plasma BK PCR of >7700 copies/mL. Immunosuppression was reduced stepwise in these patients until viral loads fell <1000/mL. Overall screening costs (including extra plasma PCR testing) were estimated at $33,450. Those with positive PCR had greater reductions in annual immunosuppression costs by year 2 ($6452 vs. $2799, p = 0.0015) compared to those with negative screens. At the end of the 2-year period, 61% of the screening costs were covered by less immunosuppressant costs. At the end of 30 months there were net savings. In summary, reductions in immunosuppression cover the cost of screening for polyoma viral infection. Longer-term follow-up is needed to ensure patient outcomes remain acceptable.

MeSH terms

  • Adult
  • Cost-Benefit Analysis
  • Female
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Kidney Diseases / economics
  • Kidney Diseases / etiology
  • Kidney Diseases / therapy*
  • Kidney Diseases / virology*
  • Kidney Transplantation / adverse effects*
  • Kidney Transplantation / economics
  • Male
  • Mass Screening / economics*
  • Middle Aged
  • Models, Economic
  • Polymerase Chain Reaction
  • Polyomavirus / metabolism*
  • Polyomavirus Infections / economics
  • Polyomavirus Infections / etiology
  • Polyomavirus Infections / therapy*
  • Polyomavirus Infections / virology*

Substances

  • Immunosuppressive Agents